CryoLife, Inc. (NYSE:CRY) issued its earnings results on Monday. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.10 by $0.02, Bloomberg Earnings reports. The firm had revenue of $47.80 million for the quarter, compared to analyst estimates of $47.02 million. CryoLife had a return on equity of 7.77% and a net margin of 5.73%. The business’s revenue was up 1.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.13 earnings per share. CryoLife updated its FY17 guidance to $40-0.43 EPS.
Shares of CryoLife (CRY) traded up 2.87% during trading on Monday, hitting $19.70. The stock had a trading volume of 155,616 shares. The firm has a market capitalization of $655.22 million, a P/E ratio of 63.96 and a beta of 0.99. CryoLife has a 1-year low of $12.99 and a 1-year high of $20.30. The stock’s 50-day moving average price is $19.29 and its 200 day moving average price is $17.96.
In other CryoLife news, VP Amy Horton sold 9,577 shares of the business’s stock in a transaction that occurred on Tuesday, June 27th. The stock was sold at an average price of $20.00, for a total transaction of $191,540.00. Following the completion of the transaction, the vice president now owns 112,282 shares in the company, valued at $2,245,640. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 6.00% of the stock is owned by insiders.
CRY has been the topic of several research reports. Zacks Investment Research upgraded CryoLife from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a research note on Thursday, June 8th. Northland Securities restated a “buy” rating and issued a $23.50 target price on shares of CryoLife in a research note on Friday, April 28th. Finally, BidaskClub lowered CryoLife from a “buy” rating to a “hold” rating in a research note on Monday. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. CryoLife currently has an average rating of “Buy” and a consensus price target of $20.80.
About CryoLife
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
